NO20081124L - Anti-CD 3 antistoff-formuleringer - Google Patents

Anti-CD 3 antistoff-formuleringer

Info

Publication number
NO20081124L
NO20081124L NO20081124A NO20081124A NO20081124L NO 20081124 L NO20081124 L NO 20081124L NO 20081124 A NO20081124 A NO 20081124A NO 20081124 A NO20081124 A NO 20081124A NO 20081124 L NO20081124 L NO 20081124L
Authority
NO
Norway
Prior art keywords
antibody formulations
formulations
doses
antibodies
diagnostic
Prior art date
Application number
NO20081124A
Other languages
English (en)
Norwegian (no)
Inventor
Marie Kosco-Vilbois
Yann Dean
Greg Christopher Andrew Elson
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of NO20081124L publication Critical patent/NO20081124L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20081124A 2005-09-12 2008-03-04 Anti-CD 3 antistoff-formuleringer NO20081124L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71631105P 2005-09-12 2005-09-12
PCT/US2006/035615 WO2007033230A2 (fr) 2005-09-12 2006-09-12 Formulations d'anticorps anti-cd3

Publications (1)

Publication Number Publication Date
NO20081124L true NO20081124L (no) 2008-05-22

Family

ID=37865544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081124A NO20081124L (no) 2005-09-12 2008-03-04 Anti-CD 3 antistoff-formuleringer

Country Status (16)

Country Link
US (2) US20100209437A1 (fr)
EP (2) EP2354162A1 (fr)
JP (1) JP2009507838A (fr)
KR (1) KR20080042905A (fr)
CN (1) CN101309703A (fr)
AR (1) AR057807A1 (fr)
AU (1) AU2006291005A1 (fr)
BR (1) BRPI0615745A2 (fr)
CA (1) CA2625815A1 (fr)
EA (1) EA014025B1 (fr)
IL (1) IL189876A0 (fr)
NO (1) NO20081124L (fr)
SG (1) SG174779A1 (fr)
UA (1) UA92505C2 (fr)
WO (1) WO2007033230A2 (fr)
ZA (1) ZA200802051B (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010611A (es) * 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
RS53008B2 (sr) * 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
PT2520590T (pt) * 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
WO2009005673A1 (fr) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
EP2173163A4 (fr) * 2007-07-06 2010-12-08 Glaxosmithkline Llc Formulations d'anticorps
US20110091447A1 (en) * 2008-03-13 2011-04-21 The Hospital For Sick Children Lymphocyte control of obesity and insulin resistance
EP2352765B1 (fr) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Anticorps monocaténaire bispécifique à domaine unique, spécifique d'espèces croisées
CA2738565C (fr) 2008-10-01 2023-10-10 Micromet Ag Anticorps monocatenaire bispecifique psmaxcd3, specifique d'especes croisees
EP2370467B1 (fr) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Anticorps monocaténaire bispécifique pscaxcd3 (cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 ou fapalpha xcd3), spécifique d'espèces croisées
WO2010132872A1 (fr) * 2009-05-15 2010-11-18 Novimmune S.A Polythérapies et méthodes utilisant des agents de modulation anti-cd3 et des antagonistes anti-tnf
JP2013508392A (ja) * 2009-10-20 2013-03-07 グラクソ グループ リミテッド 自己免疫疾患における抗ｃｄ３抗体の投薬
CN102946861B (zh) * 2010-03-01 2016-01-20 西托戴恩有限公司 浓缩蛋白制剂及其用途
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US20120189621A1 (en) 2011-01-21 2012-07-26 Yann Dean Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
US8974782B2 (en) * 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
WO2012122528A1 (fr) 2011-03-10 2012-09-13 Hco Antibody, Inc. Molécules de type anticorps tricaténaires bispécifiques
ME03440B (fr) 2011-05-21 2020-01-20 Macrogenics Inc Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
WO2013073968A2 (fr) * 2011-09-12 2013-05-23 Industrial Research Limited Agents de modulation de la signalisation cellulaire
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014110601A1 (fr) * 2013-01-14 2014-07-17 Xencor, Inc. Nouvelles protéines hétérodimères
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
PL3587448T3 (pl) * 2013-03-15 2021-11-29 Xencor, Inc. Białka heterodimeryczne
JP6541581B2 (ja) 2013-03-15 2019-07-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 低濃度抗体製剤
WO2014180577A1 (fr) * 2013-05-10 2014-11-13 Numab Ag Constructions bispécifiques et leur utilisation dans le traitement de plusieurs maladies
WO2015013671A1 (fr) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Anticorps multispécifiques, anticorps activables multispécifiques et leurs méthodes d'utilisation
ME03666B (fr) 2014-03-28 2020-10-20 Xencor Inc Anticorps bispécifiques se liant à cd38 et cd3
JP2017520575A (ja) 2014-07-01 2017-07-27 ファイザー・インク 二重特異的ヘテロ二量体ダイアボディおよびその使用
EP3172235A2 (fr) 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d'utilisation de ces anticorps
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
KR20170084326A (ko) 2014-11-26 2017-07-19 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
WO2017010874A1 (fr) 2015-07-10 2017-01-19 Merus N.V. Anticorps se liant à un cd3 humain
AU2016315656A1 (en) 2015-08-28 2018-02-01 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
EP4257613A3 (fr) 2016-06-14 2023-12-13 Xencor, Inc. Anticorps inhibiteurs de points de contrôle bispécifiques
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc CD3 binding antibodies
EP3475304B1 (fr) 2016-06-28 2022-03-23 Xencor, Inc. Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine
IL301948B1 (en) * 2016-08-29 2024-05-01 Tiziana Life Sciences Plc Anti-CD3 antibody formulations
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP7030109B2 (ja) 2016-09-14 2022-03-04 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
PE20191034A1 (es) 2016-10-14 2019-08-05 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP4215548A1 (fr) 2016-12-21 2023-07-26 Teneobio, Inc. Anticorps uniquement à chaîne lourde anti-bcma
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7381345B2 (ja) 2017-05-16 2023-11-15 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｍａｎａボディおよび使用方法
JP7247113B2 (ja) * 2017-06-06 2023-03-28 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド ミクログリアの活性化を抑制する方法
EP3642237A2 (fr) 2017-06-20 2020-04-29 Teneobio, Inc. Anticorps à chaîne lourde uniquement anti-bcma
AU2018288803A1 (en) 2017-06-20 2020-02-06 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
EP3645122A1 (fr) 2017-06-30 2020-05-06 Xencor, Inc. Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
US11427826B2 (en) 2017-08-11 2022-08-30 City of Hopw RNA aptamers against transferrin receptor (TfR)
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
JP2021508479A (ja) 2017-12-27 2021-03-11 テネオバイオ， インコーポレイテッド ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
EP3773911A2 (fr) 2018-04-04 2021-02-17 Xencor, Inc. Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
EP3781598A1 (fr) 2018-04-18 2021-02-24 Xencor, Inc. Protéines de fusion hétérodimères ciblant tim-3 contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène de tim-3
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
AU2019355971A1 (en) 2018-10-03 2021-05-06 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
CA3115089A1 (fr) 2018-10-11 2020-04-16 Inhibrx, Inc. Anticorps a domaine unique dll3 et compositions therapeutiques
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
WO2020077257A1 (fr) 2018-10-11 2020-04-16 Inhibrx, Inc. Anticorps pd-1 à domaine unique et compositions thérapeutiques associées
WO2020106704A2 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Dispositif ingestible pour administrer un agent therapeutique dans le tractus digestif
AU2019388808A1 (en) * 2018-11-29 2021-06-17 Harbour Biomed Therapeutics Limited Anti-PD-L1 antibody preparation
CA3132185A1 (fr) 2019-03-01 2020-09-10 Xencor, Inc. Anticorps heterodimeres qui se lient a enpp3 et cd3
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CA3140816A1 (fr) 2019-06-14 2020-12-17 Nathan Trinklein Anticorps a chaines lourdes multispecifiques se liant a cd22 et cd3
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
US20230287040A1 (en) 2019-11-13 2023-09-14 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
CN115894703A (zh) 2020-04-29 2023-04-04 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
WO2021231976A1 (fr) 2020-05-14 2021-11-18 Xencor, Inc. Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
WO2021252917A2 (fr) 2020-06-11 2021-12-16 Provention Bio, Inc. Procédés et compositions de prévention du diabète de type 1
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (fr) 2021-03-10 2024-01-17 Xencor, Inc. Anticorps hétérodimères qui se lient au cd3 et au gpc3
EP4323404A1 (fr) * 2021-04-16 2024-02-21 Tiziana Life Sciences PLC Administration sous-cutanée d'anticorps pour le traitement d'une maladie

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
WO1988007089A1 (fr) * 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2071478A1 (fr) * 1989-10-27 1991-04-28 Jeffery A. Bluestone Methodes et compositions favorisant l'immunopotentialisation
US6406696B1 (en) * 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US6750325B1 (en) * 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2341666T3 (es) * 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE208374T1 (de) * 1992-02-18 2001-11-15 Otsuka Kagaku Kk Beta-laktam und cepham verbindungen und ihre herstellung
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
JPH05320072A (ja) * 1992-05-20 1993-12-03 Taiho Yakuhin Kogyo Kk 虚血性脳疾患治療薬
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
US20030124119A1 (en) * 1999-12-28 2003-07-03 Tadao Yamazaki Stable antibody compositions and injection preparations
KR100913714B1 (ko) * 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
US20050118163A1 (en) * 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
US20030235583A1 (en) 2002-06-14 2003-12-25 Jeppe Sturis Combined use of a modulator of CD3 and a beta cell resting compound
US20040037826A1 (en) 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
AU2003298015A1 (en) * 2002-12-05 2004-06-30 Pdl Biopharma, Inc. Methods of treatment of ulcerative colitis with anti-cd3 antibodies
US20070224191A1 (en) * 2002-12-05 2007-09-27 Pdl Biopharma, Inc. Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies
JP4728948B2 (ja) * 2003-02-10 2011-07-20 エラン ファーマシューティカルズ，インコーポレイテッド 免疫グロブリン製剤およびその調製の方法
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
WO2005076965A2 (fr) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Immunotherapie anti-cd3 et specifique d'antigenes pour le traitement de l'auto-immunite
BRPI0511782B8 (pt) * 2004-06-03 2021-05-25 Novimmune Sa anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
CA2614640A1 (fr) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methodes de traitement de troubles auto-immuns au moyen d'anticorps monoclonaux immunosuppresseurs a toxicite reduite
WO2007033291A2 (fr) * 2005-09-14 2007-03-22 The Trustees Of Columbia University In The City Of New York Lymphocytes t cd8+ regulateurs induits par des anticorps anti-cd3
SG177907A1 (en) * 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Also Published As

Publication number Publication date
JP2009507838A (ja) 2009-02-26
ZA200802051B (en) 2008-12-31
US20100209437A1 (en) 2010-08-19
US20070065437A1 (en) 2007-03-22
BRPI0615745A2 (pt) 2011-05-24
EA014025B1 (ru) 2010-08-30
IL189876A0 (en) 2008-11-03
SG174779A1 (en) 2011-10-28
CA2625815A1 (fr) 2007-03-22
WO2007033230A3 (fr) 2007-09-13
EP2354162A1 (fr) 2011-08-10
EA200800812A1 (ru) 2008-08-29
EP1933868A2 (fr) 2008-06-25
AU2006291005A1 (en) 2007-03-22
KR20080042905A (ko) 2008-05-15
AR057807A1 (es) 2007-12-19
UA92505C2 (ru) 2010-11-10
CN101309703A (zh) 2008-11-19
WO2007033230A2 (fr) 2007-03-22

Similar Documents

Publication Publication Date Title
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
CY1115932T1 (el) Σκευασμα αντισωματος
WO2017004026A8 (fr) Anticorps anti-cd 123 et conjugués et dérivés correspondants
NO20074238L (no) Fiksert dosering av HER-antistoffer
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
UA109633C2 (uk) Антитіло людини проти тканинного фактора
NO20084878L (no) Humanisert C-kit antistoff
EA201100694A1 (ru) Антитело к cd38 человека и его применение
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
CY1115935T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20080246L (no) Anti-IGF1R-antistofformuleringer
NO20083011L (no) Modulatorer av muskarine receptorer
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
WO2009061996A3 (fr) Anticorps qui se lient à la cellule dendritique et épithéliale 205 (dec-205) humaine
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
NO20072290L (no) Organiske forbindelser.
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application